Citation Impact
Citing Papers
Antiseptics and Disinfectants: Activity, Action, and Resistance
1999 Standout
Pathophysiology of Migraine: A Disorder of Sensory Processing
2017 Standout
Systemic Targeting of CpG-ODN to the Tumor Microenvironment with Anti–neu-CpG Hybrid Molecule and T Regulatory Cell Depletion Induces Memory Responses in BALB-neuT Tolerant Mice
2008 StandoutNobel
Osteoarthritis year in review 2019: epidemiology and therapy
2020 Standout
Pharmacokinetic Properties of 2′-O-(2-Methoxyethyl)-Modified Oligonucleotide Analogs in Rats
2001
A Toll-like receptor recognizes bacterial DNA
2000 StandoutNature
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
Cancer nanomedicine: progress, challenges and opportunities
2016 Standout
TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity
2007 StandoutNobel
Potent effect of target structure on microRNA function
2007 StandoutNobel
Targeting the hepcidin–ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation
2011
Neuroblastoma: biological insights into a clinical enigma
2003 Standout
Antiinfective Applications of Toll-like Receptor 9 Agonists
2007
State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriers
2008
IAP family proteins---suppressors of apoptosis
1999 Standout
Antimutagenic effects of flavoniods, chalcones and structurally related compounds on the activity of 2--3-[4,5-ƒ] (IQ) and other heterocyclic amine mutagens from cooked food
1993
Macrophages in atherosclerosis: a dynamic balance
2013 Standout
Lack of toxicity of a STAT3 decoy oligonucleotide
2008
Nanoporous Carbohydrate Metal–Organic Frameworks
2011 StandoutNobel
Cell-free nucleic acids as biomarkers in cancer patients
2011 Standout
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
2015 Standout
Control of apoptosis and mitotic spindle checkpoint by survivin
1998 StandoutNature
Antisense therapy for cancer
2005
bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice
1998
Targeting RAS signalling pathways in cancer therapy
2003 Standout
Enhancement of DNA vaccine potency in rhesus macaques by electroporation
2004
Immunity, Inflammation, and Cancer
2010 Standout
The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses
2004 Standout
Oncomirs — microRNAs with a role in cancer
2006 Standout
Liquid biopsies come of age: towards implementation of circulating tumour DNA
2017 Standout
Detection of genotoxic activity in native hospital waste water by the umuC test
1996
Occurrence, fate and effects of pharmaceutical substances in the environment- A review
1998 Standout
Circulating mutant DNA to assess tumor dynamics
2008 Standout
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
2017 Standout
Non-coding RNAs in human disease
2011 Standout
Antisense oligonucleotides as therapeutic agents
1999
STATs in cancer inflammation and immunity: a leading role for STAT3
2009 Standout
Integrated Nanoparticle–Biomolecule Hybrid Systems: Synthesis, Properties, and Applications
2004 Standout
Normal Functional Capacity in Circulating Myeloid and Plasmacytoid Dendritic Cells in Patients with Chronic Hepatitis C
2005 StandoutNobel
Death and anti-death: tumour resistance to apoptosis
2002 Standout
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
2014 Standout
Induction of Apoptosis and Inhibition of Cell Proliferation bysurvivin Gene Targeting
1998
Effects of RNA secondary structure on cellular antisense activity
2000
Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis
2011
Biodistribution of 68Ga-labelled phosphodiester, phosphorothioate, and 2′-O-methyl phosphodiester oligonucleotides in normal rats
2005
Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics
2000
Inhibition of microRNA with antisense oligonucleotides
2007
Revealing the world of RNA interference
2004 StandoutNatureNobel
STAT3 and STAT1 mediate IL-11–dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice
2008
Antisense Pharmacodynamics: Critical Issues in the Transport and Delivery of Antisense Oligonucleotides
1999
The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells
2008 StandoutNobel
Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study
2014
Revisiting STAT3 signalling in cancer: new and unexpected biological functions
2014 Standout
Human Clinical Trials of Plasmid DNA Vaccines
2005
Toxicology of antisense therapeutics
2004
Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease
2007
New therapeutic strategies for hepatitis C
2002 StandoutNobel
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Pathways towards and away from Alzheimer's disease
2004 StandoutNature
Pathogen Recognition and Innate Immunity
2006 Standout
Gene regulation by long non-coding RNAs and its biological functions
2020 Standout
Anemia of Chronic Disease
2005 Standout
Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy
2012 StandoutNobel
Immune Recognition of Foreign DNA
1999
MicroRNA-21 Promotes Fibrosis of the Kidney by Silencing Metabolic Pathways
2012
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
Mechanisms of Insulin Action and Insulin Resistance
2018 Standout
Unc93B1 biases Toll-like receptor responses to nucleic acid in dendritic cells toward DNA- but against RNA-sensing
2009 StandoutNobel
Peripheral and central nervous system distribution of the CGRP neutralizing antibody [125I] galcanezumab in male rats
2019
Progress in the Delivery of Therapeutic Oligonucleotides: Organ/Cellular Distribution and Targeted Delivery of OligonucleotidesIn Vivo
2003
Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA
2014
Development of anticancer drugs targeting the MAP kinase pathway
2000
CpG Motifs in Bacterial DNA and Their Immune Effects
2002 Standout
A Clinical Overview of Cholinesterase Inhibitors in Alzheimer’s Disease
2002
Detection and quantification of mutations in the plasma of patients with colorectal tumors
2005
The Effects of Plant Flavonoids on Mammalian Cells:Implications for Inflammation, Heart Disease, and Cancer
2000 Standout
Pharmaceuticals of Emerging Concern in Aquatic Systems: Chemistry, Occurrence, Effects, and Removal Methods
2019 Standout
Liquid Biopsies: Genotyping Circulating Tumor DNA
2014 Standout
Thermal analysis and calorimetric methods in the characterisation of polymorphs and solvates
1995
Magnetic Nanoparticles: Design and Characterization, Toxicity and Biocompatibility, Pharmaceutical and Biomedical Applications
2012 Standout
Dendritic cell targeted HIV gag protein vaccine provides help to a DNA vaccine including mobilization of protective CD8 + T cells
2010 StandoutNobel
Targeting Foxo1 in Mice Using Antisense Oligonucleotide Improves Hepatic and Peripheral Insulin Action
2006
Phase I Clinical and Pharmacokinetic Study of Bcl-2 Antisense Oligonucleotide Therapy in Patients With Non-Hodgkin’s Lymphoma
2000
Oligonucleotide-Modified Gold Nanoparticles for Intracellular Gene Regulation
2006 StandoutScience
The role of cytokine DNAs as vaccine adjuvants for optimizing cellular immune responses
2004
Review of the genotoxicity of formaldehyde
1988
A RNA antagonist of hypoxia-inducible factor-1α, EZN-2968, inhibits tumor cell growth
2008
Current Progress on aptamer-targeted Oligonucleotide Therapeutics
2013
The binding of phosphorothioate oligonucleotides to CdS nanoparticles
2003
Works of David Monteith being referenced
Chemically Modified Oligonucleotides Exhibit Decreased Immune Stimulation in Mice
2000
In Vivo Distribution and Metabolism of a Phosphorothioate Oligonucleotide within Rat Liver after Intravenous Administration
1998
Genotoxicity of organic chemicals frequently found in the air of mobile homes
1985
Catechin inhibition of mutagenesis and alteration of DNA binding of 2-acetyl-aminofluorene in rat hepatocytes
1990
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers
2017
Tissue Disposition of 2′‐O‐(2‐methoxy) ethyl Modified Antisense Oligonucleotides in Monkeys
2003
CGRP blockade by galcanezumab was not associated with reductions in signs and symptoms of knee osteoarthritis in a randomized clinical trial
2018
Stability and inactivation of mutagenic drugs and their metabolites in the urine of patients administered antineoplastic therapy
1987
Translational Pharmacodynamics of Calcitonin Gene-Related Peptide Monoclonal Antibody LY2951742 in a Capsaicin-Induced Dermal Blood Flow Model
2015
Cytotoxicity Study of Tacrine, Structurally and Pharmacologically Related Compounds Using Rat Hepatocytes
1996
Characterization of Oligonucleotide MetabolismIn Vivovia Liquid Chromatography/Electrospray Tandem Mass Spectrometry with a Quadrupole Ion Trap Mass Spectrometer
1997
Preclinical Evaluation of the Effects of a Novel Antisense Compound Targeting C-rafKinase in Mice and Monkeys
1998
Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase.
1997
Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicological properties of phosphorothioate oligodeoxynucleotides.
1997
Safety of a GM-CSF adjuvant-plasmid DNA malaria vaccine
2001
Effects of Intravenous Infusion of Phosphorothioate Oligonucleotides on Coagulation, Complement Activation and Hemodynamics
1997
Synthetic Oligonucleotides: The Development of Antisense Therapeutics
1999
Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides.
1997
Evaluation of the Renal Effects of an Antisense Phosphorothioate Oligodeoxynucleotide in Monkeys
1999
Degradation and Inactivation of Antitumor Drugs
1993
Distribution and Excretion of a Phosphorothioate Oligonucleotide in Rats with Experimentally Induced Renal Injury
2004